Scorpion Therapeutics, Inc.

With many big pharmas anxious to fill their portfolios with new commercial sellers and biotechs running low on cash, 2025 is expected to be a big year for deals and M&A across the biopharma sector

“I’m always keeping an eye on anything that’s going to the capital markets, whether that’s interest rates... a big change in the regulatory environment...anything that impacts capital markets and inve

With many big pharmas anxious to fill their portfolios with new commercial sellers and biotechs running low on cash, 2025 is expected to be a big year for deals and M&A across the biopharma sector

Eli Lilly has seen tremendous revenue growth and become one of the most highly valued pharmaceutical companies in the world based on its GLP-1/GIP agonist tirzepatide – Mounjaro for type 2 diabetes an